Join Now

Author Archives: Natalie Themm

Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

Published in the journal PREGNANCY, the PRIME Study demonstrates significant improvements in neonatal outcomes with early risk screening and targeted interventions.

Posted in BioUtah News | Tagged | Comments Off on Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications

Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment

Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment

Posted in BioUtah News | Tagged | Comments Off on Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment

World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor

Dr. Mark Davis, discoverer of the first T-cell receptor genes and Stanford Professor, to advise the Company on immunological strategies for its novel cancer treatment platform.

Posted in BioUtah News | Tagged | Comments Off on World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor

Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing

Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing

Posted in BioUtah News | Tagged | Comments Off on Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing

SINTX 2025 Highlights

As we look back at 2025, we’re thankful for the progress our team and partners helped drive this year.

Posted in BioUtah News | Tagged | Comments Off on SINTX 2025 Highlights

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Posted in BioUtah News | Tagged | Comments Off on The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Bloom Surgical: 2025 Year In Review

2025 marked a year of significant progress of reached milestones and successes for Bloom Surgical

Posted in BioUtah News | Tagged | Comments Off on Bloom Surgical: 2025 Year In Review

Adam Barker, PhD, Named President and Chief Operations Officer of ARUP Reference Business Unit

A microbiologist, Adam Barker, PhD, was ARUP’s chief scientific officer and director of Research and Development before being named chief operations officer—now adds Reference Business Unit president to his title.

Posted in BioUtah News | Tagged | Comments Off on Adam Barker, PhD, Named President and Chief Operations Officer of ARUP Reference Business Unit

Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

The Australian patent represents the first patent granted for the Company’s new point-of-care testing platform.

Posted in BioUtah News | Tagged , | Comments Off on Co-Diagnostics Receives Grant of Australian Patent Covering Co-Dx PCR Platform Technologies

Merit Medical’s Fred Lampropoulos Honored by Nasdaq

Merit Medical’s Fred Lampropoulos Honored by Nasdaq

Posted in BioUtah News | Tagged | Comments Off on Merit Medical’s Fred Lampropoulos Honored by Nasdaq

Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million

Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million

Posted in BioUtah News | Tagged | Comments Off on Perimeter Solutions Announces Agreement to Acquire MMT for $685 Million

Freyya Recognized at Transatlantic Angel Competition (TAAC8)

Freyya Recognized at Transatlantic Angel Competition (TAAC8)

Posted in BioUtah News | Tagged | Comments Off on Freyya Recognized at Transatlantic Angel Competition (TAAC8)